TRPM2 and neoplasm: In agreement, we detected substantially reduced cells with Ki67 expression and increased cells positive for cPARP in both PC‐9/AR/shRNA and HCC827/AR/shRNA tumors treated with osimertinib, but not in their corresponding control tumor tissues exposed to osimertinib (Figure 5G), indicating an impact of TRPM2 knockdown on increasing cell sensitivity to osimertinib‐induced proliferation inhibition and apoptosis.